A drug-resistant yeast called Candida auris has spread to healthcare facilities across 27 U.S. states, with clinical cases climbing sharply between 2019 and 2021 and detections of strains resistant to the last reliable class of antifungal drugs rising alongside them. In a 2016 hospital outbreak in Colombia, roughly half the infected patients died. The fungus, which thrives on surfaces and spreads silently among critically ill patients, now poses one of the most serious infection-control challenges facing American hospitals.
Echinocandin resistance is accelerating across U.S. facilities
The Centers for Disease Control and Prevention flagged Candida auris as an urgent threat after documenting rapid growth in reported cases during 2020 and 2021, along with geographic expansion to additional states during the same period. That alarm drew on a peer-reviewed analysis of U.S. surveillance data, which documented a rise in both echinocandin-resistant and pan-resistant detections in 2021. Echinocandins are the frontline drugs used against most Candida infections, and when the fungus develops resistance to them, physicians are left with few or no effective treatments.
The pattern is especially alarming because echinocandin resistance does not emerge randomly. Genomic analysis published in the CDC’s Emerging Infectious Diseases journal has linked resistance to specific FKS1 hotspot substitutions, genetic changes in the fungus that disable the drug’s mechanism of action. Distinct clades of C. auris carrying these mutations move through facilities via colonized patients and contaminated surfaces. Once a resistant strain establishes itself in a hospital or long-term care facility, standard cleaning protocols often fail to eliminate it, especially when disinfectants without proven antifungal activity are used.
The working hypothesis among infection-control specialists is straightforward: unless screening and contact precautions expand to every facility reporting any colonization, the share of echinocandin-resistant cases will keep growing. Testing that hypothesis would require comparing resistance proportions in states that mandate screening against those that do not. No federal agency has published such a comparison, leaving a gap between the available science and the policy response. Without robust comparative data, it is difficult to know whether current containment strategies are merely slowing spread or meaningfully reducing resistant strains.
From seven cases to thousands in under a decade
The earliest known U.S. Candida auris case dates to 2013, according to CDC tracking records covering 2013 through 2022. The agency’s Morbidity and Mortality Weekly Report documented the first seven reported cases between May 2013 and August 2016. Those early detections prompted the CDC to issue a clinical alert to U.S. healthcare facilities in June 2016, warning laboratories and clinicians to watch for the organism and to report confirmed cases immediately.
The trajectory since then has been steep. The CDC’s public communications now describe a “dramatic” increase in both clinical infections and asymptomatic colonization, emphasizing that the fungus has spread to dozens of states and multiple types of healthcare settings. A 2023 agency update highlighted the rapid escalation in case counts and underscored the organism’s ability to persist on surfaces and equipment, making it difficult to eradicate once established.
Much of that acceleration occurred during and after the COVID-19 pandemic, when infection-control resources were stretched thin and long-term care facilities faced staffing shortages that made isolation protocols harder to enforce. Patients requiring mechanical ventilation, central venous catheters, or prolonged intensive care were especially vulnerable, and the same invasive devices that sustain life also provide entry points for bloodstream infections. In this environment, even a small breach in hand hygiene or environmental cleaning could allow C. auris to spread from one room or ward to another.
A hospital-associated multicenter outbreak in Colombia in 2016 offers the starkest illustration of what happens when C. auris gains a foothold. That outbreak, documented in the CDC’s Emerging Infectious Diseases journal, recorded a fatality rate of approximately 50% among infected patients. The Colombian experience became a reference point for global public health agencies, though attributing deaths directly to C. auris remains difficult because most victims are already critically ill with other conditions. As the CDC’s own summaries note, many patients have multiple comorbidities, making it challenging to separate deaths caused by the fungus from deaths in which it is one of several contributing factors.
Gaps in surveillance and stewardship data
Several questions remain unanswered despite more than a decade of tracking. State-level monthly case counts after 2021 are available only through aggregate dashboards, with no public line-list or facility-level records that would allow independent researchers to map transmission chains. Without patient-level timelines and facility identifiers, it is nearly impossible to reconstruct how often C. auris moves between hospitals, long-term acute care centers, and nursing homes, or to pinpoint where containment measures are failing.
Full genomic sequence metadata and FKS1 substitution frequencies for 2022 onward have not been published outside internal Antibiotic Resistance Laboratory Network reports, limiting the ability of outside scientists to verify whether resistance is still accelerating at the same rate. Publicly accessible genomes exist for earlier isolates, but the absence of up-to-date, linked clinical and genomic data means that trends in resistance may only become apparent after they are already entrenched. That lag is especially problematic for an organism that can colonize patients for months and spread unnoticed through shared equipment and common areas.
Direct mortality data tied specifically to U.S. cases are also absent from CDC surveillance tables and from the 2019-to-2021 Annals of Internal Medicine analysis. The 50% fatality figure cited most often comes from the 2016 Colombian outbreak study, a specific hospital cohort that cannot be generalized to all U.S. patients without additional data. Without standardized outcome reporting for C. auris bloodstream infections, including severity of underlying illness and co-infections, policymakers are left to infer the fungus’s true lethality from scattered case series and international reports.
Equally opaque is the status of antifungal stewardship. No primary document from the Department of Health and Human Services or the CDC details current stewardship interventions targeted specifically at C. auris or measures their effect on resistance rates. Hospitals may be adjusting prescribing practices, improving diagnostic turnaround times, or restricting certain antifungals, but there is no national accounting of these efforts. That makes it impossible to assess whether existing programs are slowing the trend toward echinocandin resistance or simply reacting piecemeal to local outbreaks.
What patients and families can do now
For patients in long-term care facilities and their families, the practical takeaway is direct. Anyone admitted to a facility where C. auris has been detected should ask whether the site conducts active screening for colonization and what contact precautions are in place. Key questions include whether high-risk patients are tested on admission, whether colonized individuals are cohorted or placed in single rooms, and what disinfectants are used for daily and terminal cleaning.
Families can also ask how the facility trains staff on hand hygiene and personal protective equipment, and whether it participates in regional infection-prevention collaboratives. While individual patients cannot control the broader surveillance and stewardship gaps, they can seek facilities that acknowledge C. auris openly, follow CDC guidance, and are willing to explain their protocols. In the absence of comprehensive national data, that transparency at the bedside level may be the strongest available defense against a fungus that has already proven how quickly it can adapt and spread.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
